Alivus Life Sciences Limited (NSE: ALIVUS) announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for INR 91.2 million. This strategic move aims to leverage IQGenX’s expertise in advanced formulation development, enhancing Alivus’s capabilities in oral solids, sterile injectables, and ophthalmic solutions. The acquisition will enable Alivus to expand its global customer base in the generic pharmaceutical segment.

Enhanced Formulation Development

IQGenX, founded in 2016, specializes in formulation development for highly regulated markets. This acquisition will allow Alivus to integrate end-to-end platforms offering deep scientific expertise across complex delivery formats. Alivus will now provide rigorous bioequivalence and stability studies, enabling comprehensive regulatory filings for diverse global markets.

Expanded Service Platform

The expanded service platform will cover pre-formulation studies, prototype development, process optimization, clinical supplies, and full-scale commercial manufacturing. Additionally, analytical development, methods validation, stability programs, and complete regulatory submission support will be offered. This will significantly scale up Alivus’s value proposition for global CDMO customers.

Alivus will strategically leverage IQGenX’s specialized platform alongside its own world-class API portfolio, focusing on oncology to curate a high-impact basket of differentiated, niche assets. These assets, backed by validated commercial-scale manufacturing capabilities, are primed for strategic out-licensing across multiple geographies.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alivus Life Sciences Limited

Alivus Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alivus gains 32.8% over three months and trades near its 52-week highs. The PEG stands at 4.35 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 23.3% are impressive but need to be sustained — any compression would be a red flag. RSI hits 74, a level that signals the stock runs hot. Notably, buyers drove volume on 15 recent sessions — though at these levels, some profit-taking is normal. The stock rises 32.8% in three months on 7.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Alivus Life Sciences Limited.

Alivus Life Sciences Limited (ALIVUS) breaks out, gaining +10% to ₹1342.9 on the NSE on 04 Aug 2026. This move is driven by the stock clearing its 6M resistance trendline, transitioning from a breakdown to a breakout. Alivus operates in the specialty and generic drug manufacturing segment within the healthcare sector. Today’s move appears to be company-specific, driven by technical factors rather than broader sector momentum.

Technical setup — trendlines & DMA

Currently, Alivus is trading above its 6M support trendline at ₹1176.5, which is 12.39% below today’s price, and has broken through its 6M resistance trendline at ₹1205.83, now 10.21% above it. The stock is also 10.49% above its 50-DMA at ₹1099.1 and 23.23% above its 200-DMA at ₹985.5, indicating a stretched move. Within its 52W range of ₹819.0–₹1225.0, the stock is in the upper third, suggesting that much of the recent momentum is already priced in.

Fundamentals & business context

With a PE of 24.7 and profit margins at 23.3%, Alivus’s valuation appears to be reflecting its solid earnings quality. However, the revenue CAGR of 7.6% and profit CAGR of 6.5% over the past five years suggest that the stock’s price may be somewhat stretched relative to its growth rate. The 8.9% institutional ownership indicates a cautious approach by smart money, possibly due to the stock’s overvalued PEG ratio of 3.80. There is no NSE catalyst today, making this move primarily technical.

Algorithmic scorecard

The overall algorithmic scorecard indicates a technically strong but fundamentally weaker profile. The strongest signals are the bullish trend, with the 50-DMA above the 200-DMA, and the bullish sentiment over the last 30 days, where volume on up days has been 1.31x higher than on down days. These signals suggest systematic accumulation and positive momentum. However, the weakest signals are the overvalued PEG ratio and the negligible dividend yield, which represent risks of overpricing and lack of income generation, respectively.

Company outlook

Management outlined several key forward-looking metrics and strategic initiatives. They expect to sustain EBITDA margins between 30% to 32% going forward and plan a capex of about INR 540 crores for FY27, funded through internal accruals. Capacity utilization in brownfield is expected to reach 80-90% in 2 to 3 quarters, while Solapur is projected to start with 40-50% utilization, increasing to 60-70% the following year. The CDMO business is expected to see continued momentum with new deals on the horizon. A significant revenue jump is anticipated in FY28 as capex comes online. Strategic priorities have shifted towards lateral growth and higher entry barriers to sustain profitability, with an even distribution of revenue across mature geographies and a growing presence in Japan. Capacity expansion is planned from 1,198 KL in FY24 to 2,690 KL by FY28, and R&D spend is expected to settle around 4% of sales in the next 2 to 3 years. The company also hopes to close 2 new CDMO deals in the early second half of the current year.

Get all details on ALIVUS — P&L, peers, shareholding and more on TradeAlone.

Alivus Life Sciences Limited (ALIVUS) breaks out with a +7% gain to ₹1301.0 on the NSE, clearing its 6-month resistance trendline after a period of breakdown. This move is driven by technical factors, specifically the stock’s breakout above the ₹1206 resistance level, marking a 7.3% clearance. Alivus operates in the healthcare sector, specializing in drug manufacturing, and today’s move appears to be company-specific rather than a sector-wide trend.

Technical setup — trendlines & DMA

The current trendline structure shows Alivus with a 6-month support floor at ₹1176.5, which is 9.57% below today’s price, indicating a solid base. Resistance was previously at ₹1205.83, which the stock has now broken, signaling a potential shift in momentum. The 50-DMA at ₹1099.1 is above the 200-DMA at ₹985.5, suggesting a bullish trend. The stock is currently 10.49% above the 50-DMA, indicating an extended move. In the 52-week range of ₹819.0 to ₹1225.0, the current price is in the upper third, reflecting that a significant portion of the move is already priced in.

Fundamentals & business context

With a PE of 24.7 and profit margins at 23.3%, Alivus’s valuation appears to be reflecting its solid earnings quality. The revenue CAGR of 7.6% over five years shows consistent growth, though the PEG ratio of 3.80 suggests the stock may be overvalued relative to its growth rate. Institutional holding at 8.9% indicates a cautious but present interest from smart money. There is no NSE catalyst today, making this move purely technical.

Algorithmic scorecard

The overall algorithmic scorecard reflects a technically strong but fundamentally weaker profile for Alivus. The strongest signals include excellent efficiency with a 23.3% profit margin, showcasing the company’s ability to maintain strong profits, and very low debt with a D/E ratio of 0.02, indicating excellent financial health. On the weaker side, the negligible dividend yield of 0.43% offers little income to investors, and the PEG ratio of 3.80 suggests the stock is expensive relative to its growth rate, posing a valuation risk.

Company outlook

Management outlined a confident forward guidance, expecting to sustain EBITDA margins between 30% to 32% going forward. Capex of about INR 540 crores is planned for FY27, aimed at enhancing capacity utilization, which is expected to reach 80-90% in brownfield operations within 2 to 3 quarters. The Solapur facility is projected to start with 40-50% utilization, increasing to 60-70% the following year. The CDMO business is gaining momentum with revived projects and new deals anticipated. A significant revenue jump is expected in FY28 as capacity additions come online. Strategic priorities have shifted towards lateral growth and higher entry barriers to sustain profitability, with revenue evenly distributed across mature geographies and a growing presence in Japan.

Get all details on ALIVUS — P&L, peers, shareholding and more on TradeAlone.